FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1513-1520 October 7, 2004 Number 15 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Debes, J. D. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer.

Methods We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on day 2, and 60 mg of dexamethasone in three divided doses before docetaxel, or 12 mg of mitoxantrone per square meter on day 1 plus 5 mg of prednisone twice daily. The primary end point was overall survival; secondary end points were progression-free survival, objective response rates, and post-treatment declines of at least 50 percent in serum prostate-specific antigen (PSA) levels.

Results Of 674 eligible patients, 338 were assigned to receive docetaxel and estramustine and 336 to receive mitoxantrone and prednisone. In an intention-to-treat analysis, the median overall survival was longer in the group given docetaxel and estramustine than in the group given mitoxantrone and prednisone (17.5 months vs. 15.6 months, P=0.02 by the log-rank test), and the corresponding hazard ratio for death was 0.80 (95 percent confidence interval, 0.67 to 0.97). The median time to progression was 6.3 months in the group given docetaxel and estramustine and 3.2 months in the group given mitoxantrone and prednisone (P<0.001 by the log-rank test). PSA declines of at least 50 percent occurred in 50 percent and 27 percent of patients, respectively (P<0.001), and objective tumor responses were observed in 17 percent and 11 percent of patients with bidimensionally measurable disease, respectively (P=0.30). Grade 3 or 4 neutropenic fevers (P=0.01), nausea and vomiting (P<0.001), and cardiovascular events (P=0.001) were more common among patients receiving docetaxel and estramustine than among those receiving mitoxantrone and prednisone. Pain relief was similar in both groups.

Conclusions The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.

Source Information

From Columbia University, Herbert Irving Comprehensive Cancer Center, New York (D.P.P., M.C.B.); Southwest Oncology Group Statistical Center, Seattle (C.M.T., C.M.); the University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.A.H.); the University of California, Davis, Sacramento (P.N.L.); Baylor College of Medicine, Houston (J.A.J.); the University of Massachusetts Medical Center, Worcester (M.E.T.); the Mayo Clinic, Rochester, Minn. (P.A.B.); Biobehavioral Nursing and Health Systems, University of Washington, Seattle (D.B.); the University of Arkansas for Medical Science, Little Rock (M.K.); the University of California, San Francisco, Cancer Center, San Francisco (E.J.S.); the Cleveland Clinic Foundation, Cleveland (D.R.); and the University of Colorado Health Science Center, Denver (E.D.C.).

Address reprint requests to the Southwest Oncology Group (S9916) Operations Office, 14980 Omicron Dr., San Antonio, TX 78245-3217, or at pubs{at}swog.org.

Full Text of this Article

Related Letters:

Chemotherapy for Advanced Prostate Cancer
Nabhan C., Petrylak D. P., Hussain M., Crawford E. D.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:200-201, Jan 13, 2005. Correspondence

This article has been cited by other articles:

• Sternberg, C. N., Petrylak, D. P., Sartor, O., Witjes, J. A., Demkow, T., Ferrero, J.-M., Eymard, J.-C., Falcon, S., Calabro, F., James, N., Bodrogi, I., Harper, P., Wirth, M., Berry, W., Petrone, M. E., McKearn, T. J., Noursalehi, M., George, M., Rozencweig, M. (2009). Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. JCO 27: 5431-5438 [Abstract] [Full Text]  
• Gan, L., Chen, S., Wang, Y., Watahiki, A., Bohrer, L., Sun, Z., Wang, Y., Huang, H. (2009). Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer. Cancer Res. 69: 8386-8394 [Abstract] [Full Text]  
• Ide, H., Kikuchi, E., Kono, H., Nagata, H., Miyajima, A., Nakagawa, K., Ohigashi, T., Nakashima, J., Oya, M. (2009). Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer. Jpn J Clin Oncol 0: hyp126v2-hyp126 [Abstract] [Full Text]  
• Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W., Breit, S. N., Sutherland, R. L., Henshall, S. M., Horvath, L. G. (2009). Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Res. 69: 7696-7703 [Abstract] [Full Text]  
• Dorff, T. B., Tangen, C. M., Crawford, E. D., Petrylak, D. P., Higano, C. S., Raghavan, D., Quinn, D. I., Vogelzang, N. J., Thompson, I. M. (2009). Review: Cooperative group trials -- Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. Therapeutic Advances in Medical Oncology 1: 69-77 [Abstract]  
• Drake, C. G. (2009). Immunotherapy for Prostate Cancer: Walk, Don't Run. JCO 27: 4035-4037 [Full Text]  
• SRINIVAS, S., FELDMAN, D. (2009). A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. Anticancer Res 29: 3605-3610 [Abstract] [Full Text]  
• Fung, A. S., Wu, L., Tannock, I. F. (2009). Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts. Clin. Cancer Res. 15: 5389-5395 [Abstract] [Full Text]  
• Fontana, A., Galli, L., Fioravanti, A., Orlandi, P., Galli, C., Landi, L., Bursi, S., Allegrini, G., Fontana, E., Di Marsico, R., Antonuzzo, A., D'Arcangelo, M., Danesi, R., Del Tacca, M., Falcone, A., Bocci, G. (2009). Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer. Clin. Cancer Res. 15: 4954-4962 [Abstract] [Full Text]  
• Regan, M. M., O'Donnell, E. K., Kelly, W. K., Halabi, S., Berry, W., Urakami, S., Kikuno, N., Oh, W. K. (2009). Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 0: mdp308v1-mdp308 [Abstract] [Full Text]  
• Michels, J., Ellard, S. L., Le, L., Kollmannsberger, C., Murray, N., Tomlinson Guns, E. S., Carr, R., Chi, K. N. (2009). A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 0: mdp311v1-mdp311 [Abstract] [Full Text]  
• Sonpavde, G., Periman, P. O., Bernold, D., Weckstein, D., Fleming, M. T., Galsky, M. D., Berry, W. R., Zhan, F., Boehm, K. A., Asmar, L., Hutson, T. E. (2009). Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 0: mdp323v1-mdp323 [Abstract] [Full Text]  
• Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E. Jr, Higano, C., Stadler, W. M., McCulloch, W., Dearnaley, D., Parker, C., de Bono, J. S. (2009). Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 0: mdp270v1-mdp270 [Abstract] [Full Text]  
• Hahn, N. M., Zon, R. T., Yu, M., Ademuyiwa, F. O., Jones, T., Dugan, W., Whalen, C., Shanmugam, R., Skaar, T., Sweeney, C. J. (2009). A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol 0: mdp244v1-mdp244 [Abstract] [Full Text]  
• Tu, S.-M., Mathew, P., Wong, F. C., Jones, D., Johnson, M. M., Logothetis, C. J. (2009). Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. JCO 27: 3319-3324 [Abstract] [Full Text]  
• Sternberg, C. N., Dumez, H., Van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabro, F., Collette, L., Lacombe, D., for the EORTC Genitourinary Tract Cancer Group, (2009). Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20: 1264-1269 [Abstract] [Full Text]  
• Rosenberg, J. E., Ryan, C. J., Weinberg, V. K., Smith, D. C., Hussain, M., Beer, T. M., Ryan, C. W., Mathew, P., Pagliaro, L. C., Harzstark, A. L., Sharib, J., Small, E. J. (2009). Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. JCO 27: 2772-2778 [Abstract] [Full Text]  
• Halabi, S., Vogelzang, N. J., Ou, S.-S., Owzar, K., Archer, L., Small, E. J. (2009). Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer. JCO 27: 2766-2771 [Abstract] [Full Text]  
• Sundaram, S., Durairaj, C., Kadam, R., Kompella, U. B. (2009). Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Molecular Cancer Therapeutics 8: 1655-1665 [Abstract] [Full Text]  
• Fizazi, K., Beuzeboc, P., Lumbroso, J., Haddad, V., Massard, C., Gross-Goupil, M., Di Palma, M., Escudier, B., Theodore, C., Loriot, Y., Tournay, E., Bouzy, J., Laplanche, A. (2009). Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer. JCO 27: 2429-2435 [Abstract] [Full Text]  
• Morris, M. J., Pandit-Taskar, N., Carrasquillo, J., Divgi, C. R., Slovin, S., Kelly, W. K., Rathkopf, D., Gignac, G. A., Solit, D., Schwartz, L., Stephenson, R. D., Hong, C., Delacruz, A., Curley, T., Heller, G., Jia, X., O'Donoghue, J., Larson, S., Scher, H. I. (2009). Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. JCO 27: 2436-2442 [Abstract] [Full Text]  
• Sartor, O. (2009). Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: A New Beginning?. JCO 27: 2417-2418 [Full Text]  
• Hussain, M., Goldman, B., Tangen, C., Higano, C. S., Petrylak, D. P., Wilding, G., Akdas, A. M., Small, E. J., Donnelly, B. J., Sundram, S. K., Burch, P. A., DiPaola, R. S., Crawford, E. D. (2009). Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. JCO 27: 2450-2456 [Abstract] [Full Text]  
• Dror Michaelson, M., Regan, M. M., Oh, W. K., Kaufman, D. S., Olivier, K., Michaelson, S. Z., Spicer, B., Gurski, C., Kantoff, P. W., Smith, M. R. (2009). Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20: 913-920 [Abstract] [Full Text]  
• Serrate, C., Loriot, Y., De La Motte Rouge, T., Gross-Goupil, M., Massard, C., Escudier, B., Bossi, A., Fizazi, K. (2009). Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 20: 965-965 [Full Text]  
• Liu, G., Kelly, W. K., Wilding, G., Leopold, L., Brill, K., Somer, B. (2009). An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer. Clin. Cancer Res. 15: 3172-3176 [Abstract] [Full Text]  
• Horwich, A., Parker, C., Kataja, V., On behalf of the ESMO Guidelines Working Group, (2009). Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv76-iv78 [Full Text]  
• Loriot, Y., Massard, C., Gross-Goupil, M., Di Palma, M., Escudier, B., Bossi, A., Fizazi, K. (2009). Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 20: 703-708 [Abstract] [Full Text]  
• Mir, O., Alexandre, J., Tran, A., Durand, J.-P., Pons, G., Treluyer, J.-M., Goldwasser, F. (2009). Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 20: 736-740 [Abstract] [Full Text]  
• Chavin, G., Sheinin, Y., Crispen, P. L., Boorjian, S. A., Roth, T. J., Rangel, L., Blute, M. L., Sebo, T. J., Tindall, D. J., Kwon, E. D., Karnes, R. J. (2009). Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases. Clin. Cancer Res. 15: 2174-2180 [Abstract] [Full Text]  
• Hussain, A., DiPaola, R. S., Baron, A. D., Higano, C. S., Tchekmedyian, N. S., Johri, A. R. (2009). Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 20: 492-497 [Abstract] [Full Text]  
• Spitaleri, G., Matei, D. V., Curigliano, G., Detti, S., Verweij, F., Zambito, S., Scardino, E., Rocco, B., Nole, F., Ariu, L., De Pas, T., de Braud, F., De Cobelli, O. (2009). Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Ann Oncol 20: 498-502 [Abstract] [Full Text]  
• Ramachandran, K., Gopisetty, G., Gordian, E., Navarro, L., Hader, C., Reis, I. M., Schulz, W. A., Singal, R. (2009). Methylation-Mediated Repression of GADD45{alpha} in Prostate Cancer and Its Role as a Potential Therapeutic Target. Cancer Res. 69: 1527-1535 [Abstract] [Full Text]  
• PECTASIDES, D., PECTASIDES, E., PAPAXOINIS, G., KOUMARIANOU, A., PSYRRI, A., XIROS, N., TOUNTAS, N., KAMPOSIORAS, K., PAPATSIBAS, G., FLOROS, T., GOUVERIS, P., KARAGEORGOPOULOU, S., ECONOMOPOULOS, T. (2009). Combination Chemotherapy with Docetaxel, Vinorelbine and Estramustine Phosphate in Metastatic Androgen-resistant Prostate Cancer: A Single Institution Experience. Anticancer Res 29: 769-775 [Abstract] [Full Text]  
• Millikan, R. E., Wen, S., Pagliaro, L. C., Brown, M. A., Moomey, B., Do, K.-A., Logothetis, C. J. (2008). Phase III Trial of Androgen Ablation With or Without Three Cycles of Systemic Chemotherapy for Advanced Prostate Cancer. JCO 26: 5936-5942 [Abstract] [Full Text]  
• Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C., Liu, G. (2008). A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. Clin. Cancer Res. 14: 7940-7946 [Abstract] [Full Text]  
• Berthold, D. R., Pond, G. R., de Wit, R., Eisenberger, M., Tannock, I. F., On behalf of the TAX 327 investigators, (2008). Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19: 1749-1753 [Abstract] [Full Text]  
• Narita, S., So, A., Ettinger, S., Hayashi, N., Muramaki, M., Fazli, L., Kim, Y., Gleave, M. E. (2008). GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer. Clin. Cancer Res. 14: 5769-5777 [Abstract] [Full Text]  
• Haines, I. E., Stanley, R. M. (2008). Perspective on "Chemotherapy for Advanced Prostate Cancer: 25 Years Later": Is It a Mirage or an Oasis?. JCO 26: 4049-4050 [Full Text]  
• Salama, J. K., Chmura, S. J., Mehta, N., Yenice, K. M., Stadler, W. M., Vokes, E. E., Haraf, D. J., Hellman, S., Weichselbaum, R. R. (2008). An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease. Clin. Cancer Res. 14: 5255-5259 [Abstract] [Full Text]  
• Zemskova, M., Sahakian, E., Bashkirova, S., Lilly, M. (2008). The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells. J. Biol. Chem. 283: 20635-20644 [Abstract] [Full Text]  
• Pchejetski, D., Doumerc, N., Golzio, M., Naymark, M., Teissie, J., Kohama, T., Waxman, J., Malavaud, B., Cuvillier, O. (2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Molecular Cancer Therapeutics 7: 1836-1845 [Abstract] [Full Text]  
• Thuret, R., Massard, C., Gross-Goupil, M., Escudier, B., Di Palma, M., Bossi, A., de Crevoisier, R., Chauchereau, A., Fizazi, K. (2008). The postchemotherapy PSA surge syndrome. Ann Oncol 19: 1308-1311 [Abstract] [Full Text]  
• Miller, R. E., Roudier, M., Jones, J., Armstrong, A., Canon, J., Dougall, W. C. (2008). RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Molecular Cancer Therapeutics 7: 2160-2169 [Abstract] [Full Text]  
• Smith, M. R. (2008). Rapid Testosterone Cycling and Chemotherapy for Prostate Cancer: A Way Forward or Return to the Past?. JCO 26: 2932-2933 [Full Text]  
• Rathkopf, D., Carducci, M. A., Morris, M. J., Slovin, S. F., Eisenberger, M. A., Pili, R., Denmeade, S. R., Kelsen, M., Curley, T., Halter, M., Collins, C., Fleisher, M., Heller, G., Baker, S. D., Scher, H. I. (2008). Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer. JCO 26: 2959-2965 [Abstract] [Full Text]  
• Sanfilippo, N. J., Taneja, S. S., Chachoua, A., Lepor, H., Formenti, S. C. (2008). Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer. JCO 26: 2973-2978 [Abstract] [Full Text]  
• Logothetis, C. J., Millikan, R. (2008). Chemotherapy for Advanced Prostate Cancer: 25 Years Later. JCO 26: 2423-2424 [Full Text]  
• Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., Small, E. J. (2008). Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. JCO 26: 2544-2549 [Abstract] [Full Text]  
• Nabhan, C. (2008). Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer?. JCO 26: 2413-2414 [Full Text]  
• Armstrong, A. J., Garrett-Mayer, E. L., Eisenberger, M. (2008). Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. JNCI J Natl Cancer Inst 100: 681-682 [Full Text]  
• Kim, M., Liao, J., Dowling, M. L., Voong, K. R., Parker, S. E., Wang, S., El-Deiry, W. S., Kao, G. D. (2008). TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells. Cancer Res. 68: 3440-3449 [Abstract] [Full Text]  
• Naito, S., Tsukamoto, T., Koga, H., Harabayashi, T., Sumiyoshi, Y., Hoshi, S., Akaza, H. (2008). Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in Japan. Jpn J Clin Oncol 38: 365-372 [Abstract] [Full Text]  
• Galsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., Scher, H. I. (2008). Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer. JCO 26: 2147-2154 [Abstract] [Full Text]  
• Mimeault, M., Mehta, P. P., Hauke, R., Batra, S. K. (2008). Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies. Endocr. Rev. 29: 234-252 [Abstract] [Full Text]  
• Choy, H., Park, C., Yao, M. (2008). Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue. Clin. Cancer Res. 14: 1633-1638 [Abstract] [Full Text]  
• Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., Petrylak, D., Kantoff, P., Basch, E., Kelly, W. K., Figg, W. D., Small, E. J., Beer, T. M., Wilding, G., Martin, A., Hussain, M. (2008). Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. JCO 26: 1148-1159 [Abstract] [Full Text]  
• Howard, D. N, Chambers, C., Cusano, F. (2008). Efficacy vs. effectiveness -- docetaxel and prednisone in hormone refractory prostate cancer. J Oncol Pharm Pract 14: 45-49 [Abstract]  
• Hwang, S. H., Rait, A., Pirollo, K. F., Zhou, Q., Yenugonda, V. M., Chinigo, G. M., Brown, M. L., Chang, E. H. (2008). Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Molecular Cancer Therapeutics 7: 559-568 [Abstract] [Full Text]  
• Hu, H., Li, G.-x., Wang, L., Watts, J., Combs, G. F. Jr., Lu, J. (2008). Methylseleninic Acid Enhances Taxane Drug Efficacy against Human Prostate Cancer and Down-Regulates Antiapoptotic Proteins Bcl-XL and Survivin. Clin. Cancer Res. 14: 1150-1158 [Abstract] [Full Text]  
• Roach, M. III, Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., Pilepich, M. V. (2008). Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610. JCO 26: 585-591 [Abstract] [Full Text]  
• Domingo-Domenech, J., Fernandez, P. L., Filella, X., Martinez-Fernandez, A., Molina, R., Fernandez, E., Alcaraz, A., Codony, J., Gascon, P., Mellado, B. (2008). Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 19: 269-275 [Abstract] [Full Text]  
• Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., Tannock, I. F. (2008). Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. JCO 26: 242-245 [Abstract] [Full Text]  
• Patel, P. H, Kockler, D. R (2008). Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer. The Annals of Pharmacotherapy 42: 91-98 [Abstract] [Full Text]  
• Thall, P. F., Logothetis, C., Pagliaro, L. C., Wen, S., Brown, M. A., Williams, D., Millikan, R. E. (2007). Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. JNCI J Natl Cancer Inst 99: 1613-1622 [Abstract] [Full Text]  
• Fizazi, K. (2007). The role of Src in prostate cancer. Ann Oncol 18: 1765-1773 [Abstract] [Full Text]  
• Oudard, S., Banu, E., Scotte, F., Banu, A., Medioni, J., Beuzeboc, P., Joly, F., Ferrero, J.-M., Goldwasser, F., Andrieu, J.-M. (2007). Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 18: 1828-1833 [Abstract] [Full Text]  
• Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., Eisenberger, M. (2007). A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis. Clin. Cancer Res. 13: 6396-6403 [Abstract] [Full Text]  
• Moinpour, C. M., Donaldson, G. W., Redman, M. W. (2007). Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data?. J Natl Cancer Inst Monogr 2007: 31-38 [Abstract] [Full Text]  
• Huang, C.-Y., Beer, T. M., Higano, C. S., True, L. D., Vessella, R., Lange, P. H., Garzotto, M., Nelson, P. S. (2007). Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15. Clin. Cancer Res. 13: 5825-5833 [Abstract] [Full Text]  
• Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., Eisenberger, M. (2007). Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. JCO 25: 3965-3970 [Abstract] [Full Text]  
• Shimazui, T., Kawai, K., Miyanaga, N., Kojima, T., Sekido, N., Hinotsu, S., Oikawa, T., Joraku, A., Akaza, H. (2007). Three-weekly Docetaxel with Prednisone is Feasible for Japanese Patients with Hormone-refractory Prostate Cancer: A Retrospective Comparative Study with Weekly Docetaxel Alone. Jpn J Clin Oncol 0: hym071v1-6 [Abstract] [Full Text]  
• Sharifi, N., Hamel, E., Lill, M. A., Risbood, P., Kane, C. T. Jr., Hossain, M. T., Jones, A., Dalton, J. T., Farrar, W. L. (2007). A bifunctional colchicinoid that binds to the androgen receptor. Molecular Cancer Therapeutics 6: 2328-2336 [Abstract] [Full Text]  
• Quintero, I. B., Araujo, C. L., Pulkka, A. E., Wirkkala, R. S., Herrala, A. M., Eskelinen, E.-L., Jokitalo, E., Hellstrom, P. A., Tuominen, H. J., Hirvikoski, P. P., Vihko, P. T. (2007). Prostatic Acid Phosphatase Is Not a Prostate Specific Target. Cancer Res. 67: 6549-6554 [Abstract] [Full Text]  
• Agarwal, C., Veluri, R., Kaur, M., Chou, S.-C., Thompson, J. A., Agarwal, R. (2007). Fractionation of high molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3'-di-O-gallate as a major active constituent causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis 28: 1478-1484 [Abstract] [Full Text]  
• Agarwal, C., Tyagi, A., Kaur, M., Agarwal, R. (2007). Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28: 1463-1470 [Abstract] [Full Text]  
• Small, E. J., Sacks, N., Nemunaitis, J., Urba, W. J., Dula, E., Centeno, A. S., Nelson, W. G., Ando, D., Howard, C., Borellini, F., Nguyen, M., Hege, K., Simons, J. W. (2007). Granulocyte Macrophage Colony-Stimulating Factor-Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer. Clin. Cancer Res. 13: 3883-3891 [Abstract] [Full Text]  
• Tamura, K., Furihata, M., Tsunoda, T., Ashida, S., Takata, R., Obara, W., Yoshioka, H., Daigo, Y., Nasu, Y., Kumon, H., Konaka, H., Namiki, M., Tozawa, K., Kohri, K., Tanji, N., Yokoyama, M., Shimazui, T., Akaza, H., Mizutani, Y., Miki, T., Fujioka, T., Shuin, T., Nakamura, Y., Nakagawa, H. (2007). Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles. Cancer Res. 67: 5117-5125 [Abstract] [Full Text]  
• Chen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., Chen, C.-S. (2007). Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation. Cancer Res. 67: 5318-5327 [Abstract] [Full Text]  
• Eymard, J-C, Priou, F, Zannetti, A, Ravaud, A, Lepille, D, Kerbrat, P, Gomez, P, Paule, B, Genet, D, Herait, P, Ecstein-Fraisse, E, Joly, F (2007). Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18: 1064-1070 [Abstract] [Full Text]  
• Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., Taplin, M., Vogelzang, N. J., Wade, J. L. III, Bennett, C. L., Scher, H. I. (2007). Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. JCO 25: 1596-1605 [Abstract] [Full Text]  
• Lee, K. C., Sud, S., Meyer, C. R., Moffat, B. A., Chenevert, T. L., Rehemtulla, A., Pienta, K. J., Ross, B. D. (2007). An Imaging Biomarker of Early Treatment Response in Prostate Cancer that Has Metastasized to the Bone. Cancer Res. 67: 3524-3528 [Abstract] [Full Text]  
• Frederiksen, L. J., Sullivan, R., Maxwell, L. R., Macdonald-Goodfellow, S. K., Adams, M. A., Bennett, B. M., Siemens, D. R., Graham, C. H. (2007). Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling. Clin. Cancer Res. 13: 2199-2206 [Abstract] [Full Text]  
• Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Redfern, C. H., Fehrenbacher, L., Saleh, M. N., Waterhouse, D. M., Carducci, M. A., Vicario, D., Dreicer, R., Higano, C. S., Ahmann, F. R., Chi, K. N., Henner, W. D., Arroyo, A., Clow, F. W. (2007). Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. JCO 25: 669-674 [Abstract] [Full Text]